Are you looking for ways to improve your pharmacy practice? Do you know that the price of drugs doesn’t necessarily reflect the price of their manufacture? This infographic educates about pharmacoeconomics and its application in the pharmacist practice.
Learning pharmacoeconomics can be useful to your career if you’re an healthcare professional and work with pharmaceutical companies. If you’re interested in learning more check out the course at www.infolearners.com
The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Commercialization course brings you lectures from both faculty and industry experts. With this course, recorded on campus at UCSD, we seek to share our access to top people in the field who bring an unprecedented […]Select ratingGive it 1/10Give it 2/10Give it 3/10Give it 4/10Give it 5/10Give it 6/10Give it 7/10Give it 8/10Give it 9/10Give it 10/10Cancel ratingAverage: 10 (4 votes)Drug Development Product Management SpecializationDrugsDrug CommercializationPharmaceutical IndustryPharmaceuticalPharmacoeconomicsMarketing StrategyDrug DevelopmentBiotechnologyCoursera PlusView more details Feb 7th 2022 Course AuditingCourseraUniversity of California, San DiegoHealth & SocietyMedicine & PharmacologyBeginner4 Weeks1-4 Hours/Week 41.00 EUR/monthEnglishArabicFrenchPortugueseItalianVietnameseGermanRussianEnglishSpanish
The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Commercialization course brings you lectures from both faculty and industry experts. With this course, recorded on campus at UCSD, we seek to share our access to top people in the field who bring an unprecedented range of expertise on drug commercialization. This course will cover pharmacoeconomic, marketing strategy, intellectual property strategy, portfolio management, managed markets and strategic alliances. It will also have a lecture case study from startup to success.
Class Deals by MOOC List – Click here and see Coursera’s Active Discounts, Deals, and Promo Codes.
MOOC List is learner-supported. When you buy through links on our site, we may earn an affiliate commission.
In addition, the course will discuss post-marketing clinical trials or Phase 4 trials. These are conducted after a new drug has been approved by the regulatory agencies and launched. In these studies, the new drug is prescribed in an everyday healthcare environment using a much larger group of patients. This enables new treatment uses for the new drug to be developed, comparisons with other treatments for the same indication to be made, and determination of the clinical effectiveness of the new drug in a wider variety of patient types, and more rare side effects, if any, may be detected .
Pre-marketing strategy should be instigated as early as Phase 1 clinical trials to ensure that the market’s needs are incorporated into the new drug’s overall development. Later phases when clinical results are presented at international medical conferences the marketing strategy is then refined in order to develop an awareness amongst the medical community who will be prescribing the new drug. In addition to the marketing strategy, pricing strategy and a tactical plan will be developed. Promotional material, and the sales force will be trained so that when the product is approved they can promote the drug to physician, pharmacist and nurses.
Course 3 of 3 in the Drug Development Product Management Specialization.
This course is intended as part 3 of a series: Drug Discovery, Drug Development and Drug Commercialization. We would highly recommend that you take the courses in order since it will give you a better understanding on how a drug is discovered in the lab before being tested in clinical trials and then launched in the market place.
Pharmacoeconomics in Drug Development, Jan Hirsch, Ph.D.
Intellectual Property Strategy & BioSimilars, Williams Ettouati, Pharm.D.
Marketing Pharmaceuticals & Biotechnology Drugs, Williams Ettouati, Pharm.D.
Managed Markets and Sales Strategy, Doral Fredericks, Pharm.D., MBA
Strategic Alliances in Academia, Pharma and Biotech, Williams Ettouati, Pharm. D.
Business Models and Portfolio Management
Catherine Godrecka-Bareau, CFA Director Strategy & Portfolio Management, Biosimilars, Merck
Academic Industry partnership “Various models, Various outcomes”, Remi Brouard, M.D.
From Start up to Success in Biotech, Barry Quart, Pharm.D.
Select ratingGive it 1/10Give it 2/10Give it 3/10Give it 4/10Give it 5/10Give it 6/10Give it 7/10Give it 8/10Give it 9/10Give it 10/10Cancel ratingCancel ratingGive it 1/10Give it 2/10Give it 3/10Give it 4/10Give it 5/10Give it 6/10Give it 7/10Give it 8/10Give it 9/10Give it 10/10Average: 10 (4 votes)Drug Development Product Management SpecializationDrugsDrug CommercializationPharmaceutical IndustryPharmaceuticalPharmacoeconomicsMarketing StrategyDrug DevelopmentBiotechnologyCoursera Plus
Role of pharmacoeconomic analysis in R&D decision making: when, where, how?
- PMID: 15693724
- DOI: 10.2165/00019053-200523010-00001
Pharmacoeconomics is vitally important to drug manufacturers in terms of communicating to external decision-makers (payers, prescribers, patients) the value of their products, achieving regulatory and reimbursement approval and contributing to commercial success. Since development of new drugs is long, costly and risky, and decisions must be made how to allocate considerable research and development (R&D) resources, pharmacoeconomics also has an essential role informing internal decision-making (within a company) during drug development. The use of pharmacoeconomics in early development phases is likely to enhance the efficiency of R&D resource use and also provide a solid foundation for communicating product value to external decision-makers further downstream, increasing the likelihood of regulatory (reimbursement) approval and commercial success. This paper puts the case for use of pharmacoeconomic analyses earlier in the development process and outlines five techniques (clinical trial simulation [CTS], option pricing [OP], investment appraisal [IA], threshold analysis [TA] and value of information [VOI] analysis) that can provide useful input into the design of clinical development programmes, portfolio management and optimal pricing strategy. CTS can estimate efficacy and tolerability profiles before clinical data are available. OP can show the value of different clinical programme designs, sequencing of studies and stop decisions. IA can compare expected net present value (NPV) of different product profiles or study designs. TA can be used to understand development drug profile requirements given partial data. VOI can assist risk management by quantifying uncertainty and assessing the economic viability of gathering further information on the development drug. No amount of pharmacoeconomic data can make a bad drug good; what it can do is enhance the drug developers understanding of the characteristics of that drug. Decision-making, in light of this information, is likely to be better than that without it, whether it leads to faster termination of uneconomic projects or the allocation of more appropriate resources to attractive projects.
In pharmacoeconomics online course, “College of Pharmacy” students are taught their industry with a blend of concepts and industry practices through the use of lessons, lectures, case studies, interaction with practical exercises and some research work. The pedagogy is aimed to develop the students’ decision making skills to make crucial interpretations in clinical and cost-effective research. In short, it intends to train pharmacoeconomics online course students to handle the challenges involved in this rapidly growing field.